Salla disease (SD; OMIM 604369) is a rare lysosomal storage disease that belongs to the Finnish disease heritage [
1‐
3]. SD is caused by mutations in the
SLC17A5 gene encoding a protein, sialin that is responsible for sialic acid transport across lysosomal membranes and that is required for normal CNS myelination [
4]. The prevalence of the major founder mutation, R39C (Salla
FIN mutation), is high in the northeast of Finland, where founder effect contributes to the high carrier frequency of 1:100 [
5,
6]. Most Finnish SD patients are homozygous for the R39C mutation [
6], while a few patients are compound heterozygotes harboring this Salla
FIN mutation and another
SLC17A5 mutation. The phenotype of patients with compound heterozygous mutations is more severe than that in patients with homozygous mutations [
6,
7]. The severe phenotype is characterized by young age at onset of neurodevelopmental symptoms, motor retardation, cerebral dysmyelination, cerebral and cerebellar atrophy, as well as peripheral nerve involvement [
7,
8]. Mutations in the SLC17A5 gene cause also infantile sialic acid storage disease (ISSD; OMIM 269920) that represents the most severe form of lysosomal free sialic acid diseases [
9,
10]. The children are severely affected already in utero or the first signs of the disease appear immediately after birth [
6,
11,
12], and they usually survive less than 2 years. Mutations found in these patients are different from those in SD patients.
The first symptoms of SD include nystagmus, muscular hypotonia, ataxia, and delayed motor development [
2,
7,
13], and they are usually noticed at the age of 3–12 months. All patients become intellectually disabled, but life expectancy is only slightly decreased [
2]. Epilepsy is a common symptom. On the basis of disease severity, a conventional and a severe phenotype of SD have been defined [
7]. In addition, a few patients have been reported with relatively mild symptoms [
7,
14]. Cerebral and cerebellar atrophy, dysmyelination, and corpus callosum hypoplasia are typical for all patients with SD [
15‐
17].
Motor handicap in SD begins to develop in early infancy, and the decline in motor skills is more pronounced than that in cognition after the second decade of life. We have previously carried out a cross-sectional study on neurological findings and neurocognitive profile in 41 Finnish SD patients [
7,
18]. Motor disability was severe in these patients, and the characteristic cognitive profile consisted of spatial and visual constructive impairments. Interestingly, the interactive and non-verbal communication skills were quite strong. Here we describe results from a longitudinal study on changes in neurocognitive findings during a 13-year follow-up of 24 Finnish SD patients. We found that the course of the disease was progressive, but follow-up of SD patients revealed that motor skills improved till the age of 20 years, while mental abilities improved in most patients till 40 years of age.